Perrigo sales rise 9.1% to $214.58 mil. in third quarter on strong cold/flu season.
This article was originally published in The Tan Sheet
PERRIGO SALES RISE 9.3% TO $214.6 MIL. IN THIRD QUARTER ended March 31, the private label manufacturer reported May 6. Sales in the third quarter of FY 1996 were $196.3 mil. Through nine months, sales were $648.4 mil., up 7.6%
You may also be interested in...
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.